BR112015007144A2 - uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores - Google Patents

uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores

Info

Publication number
BR112015007144A2
BR112015007144A2 BR112015007144A BR112015007144A BR112015007144A2 BR 112015007144 A2 BR112015007144 A2 BR 112015007144A2 BR 112015007144 A BR112015007144 A BR 112015007144A BR 112015007144 A BR112015007144 A BR 112015007144A BR 112015007144 A2 BR112015007144 A2 BR 112015007144A2
Authority
BR
Brazil
Prior art keywords
inhibitor
masitinib
mastoid
tyrosine kinase
kit
Prior art date
Application number
BR112015007144A
Other languages
English (en)
Inventor
Moussy Alain
Piquemal David
Kinet Jean-Pierre
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of BR112015007144A2 publication Critical patent/BR112015007144A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

resumo “uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores” a presente invenção diz respeito a um método para tratar pacientes afligidos com câncer, em que os ditos pacientes são tratados com um inibidor da tirosina cinase, inibidor de mastóide ou inibidor de c-kit, em particular masitinib, opcionalmente em combinação com pelo menos um agente antineoplástico. o inibidor da tirosina cinase, inibidor de mastóide ou inibidor de c-kit, e o pelo menos um agente antineoplástico opcional, são administrados em um regime de dosagem que compreende uma quantidade terapeuticamente eficaz. a presente invenção também diz respeito a métodos para prognosticar respostas terapêuticas para o dito tratamento em um dado paciente e portanto a identificação de subpopulações de paciente aplicáveis com base nestes fatores prognosticadores; algumas vezes aludidos como biomarcadores. um método está fundamentado no marcador clínico de intensidade de dor. o segundo método está fundamentado nos biomarcadores preditivos da expressão de gene avaliados por intermédio da expressão de rna em amostras de célula de sangue periférico coletadas antes do tratamento com um composto da invenção (isto é, um inibidor da tirosina cinase, inibidor de mastóide ou inibidor de c-kit, especialmente masitinib). vantajosamente, a presente invenção diz respeito a um método para tratar pacientes afligidos com câncer pancreático em que os ditos pacientes são tratados com um inibidor da tirosina cinase, inibidor de mastóide ou inibidor de c-kit, e em particular masitinib, opcionalmente em combinação com pelo menos um agente antineoplástico, e em particular gencitabina.
BR112015007144A 2012-10-04 2013-10-04 uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores BR112015007144A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306214 2012-10-04
PCT/EP2013/070741 WO2014053650A1 (en) 2012-10-04 2013-10-04 Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors

Publications (1)

Publication Number Publication Date
BR112015007144A2 true BR112015007144A2 (pt) 2017-12-12

Family

ID=47073382

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015007144A BR112015007144A2 (pt) 2012-10-04 2013-10-04 uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores

Country Status (20)

Country Link
US (1) US10238649B2 (pt)
EP (1) EP2903616B8 (pt)
JP (1) JP6234466B2 (pt)
KR (1) KR102149483B1 (pt)
CN (1) CN104968347A (pt)
AR (1) AR092899A1 (pt)
AU (1) AU2013326463B2 (pt)
BR (1) BR112015007144A2 (pt)
CA (1) CA2886979C (pt)
DK (1) DK2903616T3 (pt)
EA (1) EA037368B1 (pt)
ES (1) ES2656640T3 (pt)
IL (1) IL238107B (pt)
MX (1) MX369999B (pt)
NZ (1) NZ706420A (pt)
SG (1) SG11201502626PA (pt)
SI (1) SI2903616T1 (pt)
TW (1) TWI609686B (pt)
WO (1) WO2014053650A1 (pt)
ZA (1) ZA201503054B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201514311A (zh) * 2013-10-04 2015-04-16 Ab Science 用於判定胰臟癌預後之方法
RU2016147946A (ru) * 2014-05-08 2018-06-08 Онкоэтикс Гмбх Способ лечения трижды негативного рака молочной железы с использованием тиенотриазолодиазепиновых соединений
WO2016062290A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 氨苯蝶啶药物在用于制备治疗癌症的医药组合物中的用途
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
LT3423105T (lt) 2016-03-02 2021-09-10 Eisai R&D Management Co., Ltd. Antikūno-vaisto konjugatai eribulino pagrindu ir jų panaudojimo būdai
HUE057398T2 (hu) * 2016-03-25 2022-05-28 Ab Science A masitinib alkalmazása egy amiotrófiás laterálszklerózisos beteg alpopuláció kezelésére
CN107267454A (zh) * 2016-04-07 2017-10-20 北京京蒙高科干细胞技术有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
WO2018144764A1 (en) * 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
US20210398672A1 (en) * 2018-10-29 2021-12-23 Northwestern University Big Data-Driven Personalized Management of Chronic Pain
WO2020115108A1 (en) * 2018-12-06 2020-06-11 Sørlandet Sykehus Hf Egfr inhibitors and their use in the treatment of neuroathic pain
WO2020115261A1 (en) * 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CN114214396A (zh) * 2020-06-30 2022-03-22 宁波市康宁医院(宁波市精神疾病预防控制中心、宁波市微循环与莨菪类药研究所) Gabrd甲基化作为抗海洛因复吸靶点的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450302B2 (en) * 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
DK1525200T3 (da) 2002-08-02 2007-12-03 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoler til sygdomsbehandling
WO2007015935A2 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
US20100143935A1 (en) * 2006-12-01 2010-06-10 Apocell, Inc. c-KIT Phosphorylation in Cancer
WO2008084103A1 (en) 2007-01-12 2008-07-17 Ab Science Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors
MX2009008665A (es) 2007-02-13 2009-08-21 Ab Science Procedimiento para la sintesis de compuestos de 2-aminotiazol como inhibidores de quinasa.
US20120264639A1 (en) 2009-11-04 2012-10-18 Jen Jen Yeh Methods and compositions for predicting survival in subjects with cancer
AR080096A1 (es) * 2010-02-01 2012-03-14 Ab Science Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
WO2012170640A1 (en) * 2011-06-07 2012-12-13 The Trustees Of Columbia University In The City Of New York Methods and compositions for trail-drug combination therapy

Also Published As

Publication number Publication date
ES2656640T3 (es) 2018-02-27
DK2903616T3 (da) 2018-01-29
CN104968347A (zh) 2015-10-07
MX369999B (es) 2019-11-28
AU2013326463B2 (en) 2018-01-18
JP6234466B2 (ja) 2017-11-22
KR102149483B1 (ko) 2020-08-28
WO2014053650A1 (en) 2014-04-10
SI2903616T1 (en) 2018-02-28
TW201414475A (zh) 2014-04-16
EA037368B1 (ru) 2021-03-19
KR20150092739A (ko) 2015-08-13
JP2015532296A (ja) 2015-11-09
NZ706420A (en) 2018-08-31
EP2903616B8 (en) 2018-02-07
US20150272945A1 (en) 2015-10-01
CA2886979A1 (en) 2014-04-10
CA2886979C (en) 2021-01-05
SG11201502626PA (en) 2015-05-28
TWI609686B (zh) 2018-01-01
EP2903616A1 (en) 2015-08-12
US10238649B2 (en) 2019-03-26
EP2903616B1 (en) 2017-12-13
ZA201503054B (en) 2016-11-30
EA201500373A1 (ru) 2016-02-29
MX2015004264A (es) 2015-10-12
IL238107B (en) 2018-03-29
AR092899A1 (es) 2015-05-06
AU2013326463A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
BR112015004229A2 (pt) ensaios de diagnósticos e kits para a deteção de receptor 1 do folato
BR112016008694A2 (pt) Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
BR112015012536A2 (pt) tratamento de câncer com inibidores heterocíclicos da glutaminase
BR112012012610A2 (pt) terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
BRPI0907637A8 (pt) biomarcadores p53
BR112012020101A2 (pt) método diagnósticos e terapêuticos usando anticorpos anti-cd200.
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112014009276A2 (pt) uso de inibidores de tirosina quinase de bruton (btk)
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
CY1123043T1 (el) Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων
BR112018074981A2 (pt) tratamentos de câncer
BR112014016163A8 (pt) piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112012022943A2 (pt) inibidores de syk de imidazopiridnas
BR112014024219A8 (pt) Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
DE602006011607D1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
BR112014024487A2 (pt) métodos para aumentar a eficácia da terapia baseada em cd37

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]